A number of monoclonal antibody therapies targeting IgE (such as omalizumab) or eosinophilic inflammation (such as mepolizumab, an anti‐IL5 monoclonal antibody) have been developed for severe asthma but have utility in ABPA.66 Here, IL5 is linked to asthma.